D.A. Davidson & Co’s ImmunityBio IBRX Stock Holding History

D.A. Davidson & Co’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.72M	Sell	538,924 -19,285	-3%	-$146K	0.03%	438
2026 Q1	$4.28M	Buy	+558,209	New	+$3.82M	0.03%	449

Other funds holding IBRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

D.A. Davidson & Co's IBRX Position: Q2 2026 in Review

D.A. Davidson & Co reduced its ImmunityBio (IBRX) stake by 3.5% in Q2 2026, selling an estimated $146K and leaving 538,924 shares worth $4.72M. The position accounts for 0.03% of the portfolio, ranked #438.

D.A. Davidson & Co first reported a position in IBRX in Q1 2026 and has held it in 2 quarters since. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

D.A. Davidson & Co held 538,924 shares of ImmunityBio worth $4.72M as of Q2 2026.
D.A. Davidson & Co sold 19,285 ImmunityBio shares in Q2 2026, an estimated $146K.
ImmunityBio made up 0.03% of D.A. Davidson & Co's portfolio in Q2 2026, its #438 holding.
D.A. Davidson & Co first reported a position in ImmunityBio in Q1 2026 and has held it in 2 quarters since.
405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on D.A. Davidson & Co's 13F filing for Q2 2026, filed 24 Jul 2026.